Aratana Gets Rights To Two Compounds For Animal Use

Posted: March 4, 2011, 5:25 p.m., EDT



Published:

Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use.

As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales.

The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases.

The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana.

Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing.


Related story: Aratana Enters Animal Health Industry with $20 Million in Funding

 

 

<Home>

Archive »Read More

Merck Awards $5,000 Student Scholarships

Merck Animal Health recognizes 15 veterinary students interested in bovine medicine.

Jaguar Animal Health Has Taste for New Drugs

Gastrointestinal drug developer Jaguar Animal Health files its eighth Investigational New Animal Drug application.

OSU Vet College Raises Funds for Cancer Research

The Ohio State University College of Veterinary Medicine is once again participating in Pelotonia, an annual fundraiser for cancer research.

Add your comment:

Events


Show More...